Overview
LyGenesis is a clinical-stage regenerative medicine company developing a novel platform that leverages the body’s own lymph nodes as biological bioreactors to grow functioning ectopic organs. Using minimally invasive delivery of allogeneic donor cells, the company is advancing therapies designed to restore organ function and address diseases associated with organ failure, metabolic dysfunction, immune decline, and aging.
Unlike traditional transplantation approaches, LyGenesis’ proprietary technology enables a single donor organ to potentially treat up to 50 patients, creating a scalable regenerative medicine solution that addresses the global shortage of transplantable organs while significantly expanding patient access. The platform is being developed across liver, pancreas, thymus, and kidney applications with therapeutic potential spanning end-stage organ disease, Type 1 diabetes, immune tolerance induction, immune system rejuvenation, and age-related degenerative conditions.
By combining scalable manufacturing, minimally invasive delivery, and a novel approach that leverages the body’s own regenerative capacity, LyGenesis is developing a platform that has the potential to expand access to organ replacement therapies while addressing broader applications in immune function, metabolic disease, and age-related decline.